PubRank

Nick Finer

Author PubWeight™ 41.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 6.50
2 Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010 4.52
3 Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007 2.56
4 Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008 1.59
5 Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 2006 1.46
6 Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes Care 2013 1.41
7 Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012 1.37
8 Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity (Silver Spring) 2008 1.34
9 Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. Br J Gen Pract 2013 1.04
10 Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One 2013 0.97
11 Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism 2009 0.97
12 Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). Am J Clin Nutr 2003 0.92
13 Act now against new NHS competition regulations: an open letter to the BMA and the Academy of Medical Royal Colleges calls on them to make a joint public statement of opposition to the amended section 75 regulations. BMJ 2013 0.91
14 The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg 2007 0.91
15 Action on obesity: comprehensive care for all. Clin Med 2013 0.88
16 ABC of obesity. Management: part II--drugs. BMJ 2006 0.85
17 Engaging patients, clinicians and health funders in weight management: the Counterweight Programme. Fam Pract 2008 0.85
18 Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab (Lond) 2009 0.83
19 Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity (Silver Spring) 2011 0.83
20 Obesity and risk of myocardial infarction: the INTERHEART study. Lancet 2006 0.82
21 Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing. J Hypertens 2015 0.82
22 Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens. Obesity (Silver Spring) 2009 0.81
23 Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2009 0.80
24 The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period. BMC Endocr Disord 2010 0.79
25 Criteria for EASO-collaborating centres for obesity management. Obes Facts 2011 0.78
26 Latent autoimmune diabetes in adults presenting as diabetes "recurrence" after bariatric surgery: a case report. Diabetes Care 2013 0.77
27 Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens 2014 0.77
28 Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. J Cardiovasc Pharmacol 2008 0.77
29 The Eating Disorder Inventory in a UK National Health Service Obesity Clinic and its response to modest weight loss. Eat Behav 2002 0.77
30 Withdrawal of sibutramine. Editorial is judgment in advance of the facts. BMJ 2010 0.77
31 Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Horm IGF Res 2007 0.76
32 Assessment of acute and chronic pharmacological effects on energy expenditure and macronutrient oxidation in humans: responses to ephedrine. J Obes 2010 0.75
33 Aspartame and its effects on health: approach seems simplistic in electronic responses to editorial. BMJ 2005 0.75
34 Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Asia Pac J Clin Nutr 2006 0.75
35 Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. J Hypertens 2016 0.75
36 Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. J Cardiovasc Med (Hagerstown) 2017 0.75
37 Obesity Management in Europe: Current Status and Objectives for the Future. Obes Facts 2016 0.75